Literature DB >> 20582153

Possible applications for replicating HIV 1 vectors.

Atze T Das1, Rienk E Jeeninga, Ben Berkhout.   

Abstract

Since its discovery some 25 years ago, much has been learned about HIV type 1 and the molecular details of its replication cycle. This insight has been used to develop lentiviral vector systems that have advantages over conventional retroviral vector systems. For safety reasons, the lentiviral vector systems are replication incompetent and the risk of generating a replication competent virus has been minimized. Nevertheless, there may be certain applications for replication competent HIV based vector systems, and we will review our activities in this particular field. This includes the generation of a conditionally replicating HIV 1 variant as a safe live attenuated virus vaccine, the construction of mini HIV variants as cancer selective viruses for virotherapy against leukemia, and the use of a conditionally live anti HIV gene therapy vector. Although safety concerns will undoubtedly remain for the use of replication competent HIV based vector systems, some of the results in cell culture systems are very promising and warrant further testing in appropriate animal models.

Entities:  

Year:  2010        PMID: 20582153      PMCID: PMC2889699          DOI: 10.2217/hiv.10.20

Source DB:  PubMed          Journal:  HIV Ther        ISSN: 1758-4329


  95 in total

1.  Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance.

Authors:  Joseph Anderson; Akhil Banerjea; Ramesh Akkina
Journal:  Oligonucleotides       Date:  2003

2.  A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication.

Authors:  Ellen M Westerhout; Monique Vink; P C Joost Haasnoot; Atze T Das; Ben Berkhout
Journal:  Mol Ther       Date:  2006-05-11       Impact factor: 11.454

3.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

4.  Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.

Authors:  O ter Brake; N Legrand; K J von Eije; M Centlivre; H Spits; K Weijer; B Blom; B Berkhout
Journal:  Gene Ther       Date:  2008-07-31       Impact factor: 5.250

5.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

6.  Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.

Authors:  Christophe Butticaz; Angela Ciuffi; Miguel Muñoz; Jérôme Thomas; Alan Bridge; Stephanie Pebernard; Richard Iggo; Pascal Meylan; Amalio Telenti
Journal:  Antivir Ther       Date:  2003-10

7.  Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.

Authors:  Erwei Song; Sang-Kyung Lee; Derek M Dykxhoorn; Carl Novina; Dong Zhang; Keith Crawford; Jan Cerny; Phillip A Sharp; Judy Lieberman; N Manjunath; Premlata Shankar
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

8.  HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.

Authors:  Ellen M Westerhout; Marcel Ooms; Monique Vink; Atze T Das; Ben Berkhout
Journal:  Nucleic Acids Res       Date:  2005-02-01       Impact factor: 16.971

9.  A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs.

Authors:  Olivier ter Brake; Ben Berkhout
Journal:  J RNAi Gene Silencing       Date:  2005-10-14

10.  Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants.

Authors:  Troels T Nielsen; Johan Jakobsson; Nina Rosenqvist; Cecilia Lundberg
Journal:  BMC Biotechnol       Date:  2009-02-24       Impact factor: 2.563

View more
  1 in total

1.  Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.

Authors:  Carmen Álvarez-Fernández; Alberto Crespo Guardo; Javier García-Pérez; Felipe García; Julia Blanco; Laura Escribà-García; Jose Maria Gatell; Jose Alcamí; Montserrat Plana; Sonsoles Sánchez-Palomino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.